Nasdaq CopenhagenIFRS · DKK

FERROSAN MEDICAL DEVICES A/S

FERROSAN MEDICAL DEVICES A/S is a Denmark-based medical devices company focused on products used to manage bleeding in surgical and other hospital procedures. The business develops, manufactures, and commercializes biomaterial-based hemostatic products and related device solutions through a multi-site operating structure.

Revenue1,079m DKK
+8.2 %y/y
Operating profit (EBIT)218m DKK
−25.1 %y/y
EBIT margin20.2%
−9.0 ppy/y
Net income33.1m DKK
−65.3 %y/y
Free cash flow-41.6m DKK
−1,817.5 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

02505007501,0001,250m DKK2021: 720 m DKK2021: EBIT 187 m DKK20212022: 810 m DKK2022: EBIT 213 m DKK20222023: 893 m DKK2023: EBIT 189 m DKK20232024: 997 m DKK2024: EBIT 291 m DKK20242025: 1,079 m DKK2025: EBIT 218 m DKK20251,079218
RevenueOperating profit (EBIT)

Business

Share of revenue
Hemostatic products70 %

Absorbable products used to control bleeding during surgery and procedures.

Biomaterial devices20 %

Gelatin-based and other biomaterial device platforms for surgical use.

Product development10 %

Development of new biomaterial device products and related applications.

Customers

The company sells into hospitals and surgical care settings that need dependable bleeding-control products for operating rooms and procedural specialties. Its customer base is primarily healthcare providers and healthcare procurement organizations that buy these products for use in surgery, trauma care, and other invasive procedures. Demand is tied to clinical adoption, hospital purchasing standards, and the need for effective hemostasis in complex procedures.

Hospitals and hospital systems

Buy hemostatic products for routine and complex procedures where bleeding control is critical.

Surgical departments

Use products in operating rooms across cardiovascular, spine, general, and other surgeries.

Procurement and supply chain organizations

Select products based on clinical performance, availability, and contracting terms.

Medical distributors

May support access to hospital customers in certain markets and channels.

Strategy

The company’s strategy centers on advancing biomaterial-based device products, including completed and in-progress development projects. It also emphasizes product pipeline development, impairment monitoring of development assets and goodwill, and maintaining operational capacity across its manufacturing footprint.

Develop biomaterial device productsMedium term

New products expand the addressable market and support long-term pipeline value.

Support surgical hemostasis portfolioShort term

Core products must remain clinically relevant and reliable to retain hospital use.

Preserve asset value through testingShort term

Development projects, trademarks, and goodwill require regular impairment assessment.

Geography

FERROSAN MEDICAL DEVICES operates from Denmark and reports operational control over two sites, including a site in Poland mentioned in its sustainability disclosures. The available report excerpt does not provide a full revenue-by-country split, so the profile reflects the company’s known Nordic and European operating footprint rather than an exact sales map.

Risks

The main risks are tied to clinical adoption, regulatory certification, and the success of development projects in a specialized medical device market. The company also faces execution risk from manufacturing operations, commodity and energy inputs, and impairment risk if expected product cash flows do not materialize.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory and certification limits1Development project underperformance2Hospital demand and procurement pressure3Manufacturing and site disruption4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory and certification limitsImpact: HighLikelihood: Medium

    Some uses may fall outside product certifications, which can constrain market access and claims.

    Exposure: SPONGOSTAN certification scope

  2. Development project underperformanceImpact: HighLikelihood: Medium

    Capitalized development assets depend on future sales and technical success.

    Exposure: Biomaterial Devices pipeline

  3. Hospital demand and procurement pressureImpact: MediumLikelihood: High

    Sales depend on hospital budgets, purchasing cycles, and clinical preferences.

    Exposure: Surgical end markets

  4. Manufacturing and site disruptionImpact: MediumLikelihood: Medium

    Production is concentrated in a small number of controlled sites, increasing operational dependency.

    Exposure: Two operational sites

Accounting

Judgemental items
Development project capitalization

Capitalized biomaterial projects depend on future economic benefits and can be impaired if forecasts weaken.

Impact: Affects intangible assets and operating profit

Goodwill impairment

Goodwill is allocated to Biomaterial Devices and tested against future cash flow assumptions.

Impact: Can create large non-cash charges

Value-in-use forecasting

Recoverable amounts rely on long-range budget assumptions and market growth estimates.

Impact: Highly sensitive to discount rates and sales forecasts

Sustainability measurement changes

Energy and waste methodology changes make reported ESG metrics less comparable year to year.

Impact: Affects trend analysis rather than financial statements

Publicly listed companies with a comparable business focus.

Last updated: 24/10/2026